



ינואר 2026

עדכון עלון לרופא לתכשיר:

Tecartus®

Cells dispersion for infusion (brexucabtagene autoleucel)

ההתוויה הרשומה לתכשיר בישראל:

Tecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor unless ineligible to BTK inhibitor.

Limitation of use: Tecartus is not indicated for the treatment of patients with active central nervous system lymphoma.

Tecartus is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

רופאים ורוקחים נכבדים,
חברת גלייד סיאנסז ישראל בע"מ מבקשת להודיעיכם על עדכון עלונים לתכשיר בנדון.
השינויים מסומנים בעلون המצורף כאשר הטקסט המודגש **באדום** הוסיף לעלון ואילו הטקסט המוחק **בקוץ-חוצה**
נגרע ממנו. הסימונים **בצהוב** הינט החמורים במידע הבטיחותי.
העדכנים המשמעותיים ביותר מופיעים במכtab זה, קיימים עדכנים מינוריים נוספים.

העלונים לרופא ולצרכן נשלחו לפרסום במאגר התרופות שבאתר משרד הבריאות
<https://israeldrugs.health.gov.il/#!/byDrug/drugs/index.html>

כמו כן ניתן לקבלם מודפסים על ידי פניה לבעל הרישום:
גלייד סיאנסז ישראל בע"מ, רחוב החרש 4, ת.ד. 6090, פארק העסקים הוד השרון 4524075, ישראל
התכשיר זמין בכל קופות החולים.

ברכה,
מניה מל
רוקחת ממונה, גלייד סיאנסז ישראלי בע"מ

העדכוניים המהותיים בעלון לרופא:

...

4.4 Special warnings and precautions for use

- Cytokine release syndrome

Nearly all patients experienced some degree of CRS. Severe CRS, which can be fatal, was observed with Tecartus with a median time to onset of 3 days (range: 1 to 13 days). Patients must be closely monitored for signs or symptoms of these events, such as high fever, hypotension, hypoxia, chills, tachycardia and headache (see section 4.8). ~~CRS is to be managed at the physician's discretion, based on the patient's clinical presentation and according to the CRS management algorithm provided in Table 1.~~

Diagnosis of CRS requires excluding alternate causes of systemic inflammatory response, including infection.

Management of cytokine release syndrome associated with Tecartus

At least 1 dose per patient of tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, must be on site and available for administration prior to Tecartus infusion. The qualified treatment centre must have access to an additional dose of tocilizumab within 8 hours of each previous dose.

~~Treatment algorithms have been developed to ameliorate some of the CRS symptoms experienced by patients on Tecartus. These include the use of tocilizumab or tocilizumab and corticosteroids, as summarised in Table 1. Patients who experience Grade 2 or higher CRS (e.g. hypotension, not responsive to fluids, or hypoxia requiring supplemental oxygenation) must be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or life threatening CRS, consider intensive care supportive therapy. The management of patients should be conducted based on the patient's clinical presentation and in accordance with applicable local institutional and/or national or European/international clinical guidelines. Physicians are advised to exercise clinical judgment consistent with these standards.~~

CRS has been known to be associated with end organ dysfunction (e.g., hepatic, renal, cardiac, and pulmonary). In addition, worsening of underlying organ pathologies can occur in the setting of CRS. Patients with medically significant cardiac dysfunction must be managed by standards of critical care and measures such as echocardiography is to be considered. In some cases, macrophage activation syndrome (MAS) and haemophagocytic lymphohistiocytosis (HLH) may occur in the setting of CRS.

Evaluation for haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is to be considered in patients with severe or unresponsive CRS. HLH/MAS should be managed per local institutional and/or national or European/international clinical guidelines.

Tecartus continues to expand and persist following administration of tocilizumab and corticosteroids. Tumour necrosis factor (TNF) antagonists are not recommended for management of Tecartus-associated CRS.

Table 1 — CRS grading and management guidance

CRS Grade (a)	Tocilizumab	Corticosteroids
Grade 1 Symptoms require symptomatic treatment only (e.g., fever, nausea, fatigue, headache, myalgia, malaise).	If not improving after 24 hours, administer tocilizumab 8 mg/kg intravenously over 1 hour (not to exceed 800 mg).	N/A

CRS Grade (a)	Tocilizumab	Corticosteroids
Grade 2 Symptoms require and respond to moderate intervention. Oxygen requirement less than 40% FiO_2 or hypotension responsive to fluids or low dose of one vasopressor or Grade 2 organ toxicity (b).	Administer tocilizumab (c) 8 mg/kg intravenously over 1 hour (not to exceed 800 mg). Repeat tocilizumab every 8 hours as needed if not responsive to intravenous fluids or increasing supplemental oxygen. Limit to a maximum of 3 doses in a 24 hour period; maximum total of 4 doses if no clinical improvement in the signs and symptoms of CRS, or if no response to second or subsequent doses of tocilizumab; consider alternative measures for treatment of CRS. If improving, discontinue tocilizumab.	If no improvement within 24 hours after starting tocilizumab, manage as per Grade 3. If improving, taper corticosteroids, and manage as Grade 1.
Grade 3 Symptoms require and respond to aggressive intervention. Oxygen requirement greater than or equal to 40% FiO_2 or hypotension requiring high dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis.	Per Grade 2	Administer methylprednisolone 1 mg/kg intravenously twice daily or equivalent dexamethasone (e.g., 10 mg intravenously every 6 hours) until Grade 1, then taper corticosteroids. If improving, manage as Grade 2. If not improving, manage as Grade 4.
Grade 4 Life threatening symptoms. Requirements for ventilator support or continuous veno venous haemodialysis or Grade 4 organ toxicity (excluding transaminitis).	Per Grade 2	Administer methylprednisolone 1000 mg intravenously per day for 3 days. If improving, taper corticosteroids, and manage as Grade 3. If not improving, consider alternate immunosuppressants.

N/A = not available/not applicable

(a) Lee et al 2014.

(b) Refer to Table 2 for management of neurologic adverse reactions.

(c) Refer to tocilizumab summary of product characteristics for details.

- Neurologic adverse reactions

Severe neurologic adverse reactions, also known as immune effector cell-associated neurotoxicity syndrome (ICANS), have been observed in patients treated with Tecartus, which could be life-threatening or fatal. The median time to onset was 7 days (range: 1 to 262 days) following Tecartus infusion (see section 4.8).

Patients who experience Grade 2 or higher neurologic toxicity/ICANS must be monitored with continuous cardiac telemetry and pulse oximetry. Provide intensive care supportive therapy for severe or life threatening neurologic toxicity/ICANS. Non sedating, anti seizure medicines are to be considered as clinically indicated for Grade 2 or higher adverse reactions. Treatment algorithms have been developed to ameliorate the neurologic adverse reactions experienced by patients on Tecartus. These include the use of tocilizumab (if concurrent CRS) and/or corticosteroids for moderate, severe, or life threatening neurologic adverse reactions as summarised in Table 2. The management of patients should be conducted based on the patient's clinical presentation and in accordance with applicable local institutional and/or national or European/international clinical guidelines. Physicians are advised to exercise clinical judgment consistent with these standards.

Table 2 — Neurologic adverse reaction/ICANS grading and management guidance

Grading assessment	Concurrent CRS	No concurrent CRS
Grade 2	<p>Administer tocilizumab as per Table 1 for management Grade 2 CRS.</p> <p>If not improving within 24 hours after starting tocilizumab, administer dexamethasone 10 mg intravenously every 6 hours until the event is Grade 1 or less, then taper corticosteroids.</p> <p>If improving, discontinue tocilizumab.</p> <p>If still not improving, manage as Grade 3.</p> <p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p>	<p>Administer dexamethasone 10 mg intravenously every 6 hours until the event is Grade 1 or less.</p> <p>If improving, taper corticosteroids</p>
Grade 3	<p>Administer tocilizumab as per Table 1 for management of Grade 2 CRS.</p> <p>In addition, administer dexamethasone 10 mg intravenously with the first dose of tocilizumab and repeat dose every 6 hours.</p> <p>Continue dexamethasone use until the event is Grade 1 or less, then taper corticosteroids.</p> <p>If improving, discontinue tocilizumab and manage as Grade 2.</p> <p>If still not improving, manage as Grade 4.</p> <p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p>	<p>Administer dexamethasone 10 mg intravenously every 6 hours.</p> <p>Continue dexamethasone use until the event is Grade 1 or less, then taper corticosteroids.</p> <p>If not improving, manage as Grade 4.</p>
Grade 4	<p>Administer tocilizumab as per Table 1 for management of Grade 2 CRS.</p> <p>Administer methylprednisolone 1000 mg intravenously per day with first dose of tocilizumab and continue methylprednisolone 1000 mg intravenously per day for 2 more days.</p> <p>If improving, then manage as Grade 3.</p> <p>If not improving, consider alternate immunosuppressants.</p> <p>Consider non-sedating, anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis.</p>	<p>Administer methylprednisolone 1000 mg intravenously per day for 3 days.</p> <p>If improving, then manage as Grade 3.</p> <p>If not improving, consider alternate immunosuppressants.</p>